Rialdi, Alex
Duffy, Mary
Scopton, Alex P.
Fonseca, Frank
Zhao, Julia Nanyi http://orcid.org/0000-0002-4352-7748
Schwarz, Megan
Molina-Sanchez, Pedro
Mzoughi, Slim
Arceci, Elisa
Abril-Fornaguera, Jordi http://orcid.org/0000-0002-5871-4052
Meadows, Austin
Ruiz de Galarreta, Marina
Torre, Denis
Reyes, Kyna
Lim, Yan Ting
Rosemann, Felix http://orcid.org/0000-0002-1649-3247
Khan, Zaigham M. http://orcid.org/0000-0002-2471-4054
Mohammed, Kevin
Wang, Xuedi
Yu, Xufen http://orcid.org/0000-0001-7794-7890
Lakshmanan, Manikandan
Rajarethinam, Ravisankar http://orcid.org/0000-0001-9249-7840
Tan, Soo Yong
Jin, Jian http://orcid.org/0000-0002-2387-3862
Villanueva, Augusto http://orcid.org/0000-0003-3585-3727
Michailidis, Eleftherios http://orcid.org/0000-0002-9907-4346
De Jong, Ype P.
Rice, Charles M.
Marazzi, Ivan
Hasson, Dan
Llovet, Josep M. http://orcid.org/0000-0003-0547-2667
Sobota, Radoslaw M. http://orcid.org/0000-0002-2455-2526
Lujambio, Amaia http://orcid.org/0000-0002-2798-1481
Guccione, Ernesto http://orcid.org/0000-0001-7764-5307
Dar, Arvin C. http://orcid.org/0000-0003-0318-4848
Article History
Received: 21 September 2022
Accepted: 5 July 2023
First Online: 3 August 2023
Competing interests
: A.R., M.D., A.P.S., S.M., P.M.S., A.L., E.G. and A.C.D. are inventors on a patent application describing the use of WNTinib in <i>CTNNB1</i>-mutant tumors (patent no. 63/108,728). A.C.D. and A.P.S. are inventors on a patent describing WNTinib composition of matter (patent no. 16/325,218). The Guccione laboratory received research funds from Prelude Therapeutics (for unrelated projects). E.G. is a cofounder of Immunoa Pte.Ltd. A.C.D. is a cofounder, shareholder, consultant and advisory board member of Nested Therapeutics. A.C.D. and E.G. are cofounders, shareholders, consultants and advisory board members of Prometeo Therapeutics.The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc. J.M.L. receives research support from Eisai Inc, Bayer HealthCare Pharmaceuticals, Ipsen and consulting fees from Eisai Inc, Merck, Eli Lilly, Bayer HealthCare Pharmaceuticals, Genentech, Roche, AstraZeneca, Bristol-Myers Squibb, Ipsen, Glycotest, Exelixis, Mina alpha and Boston Scientific. The remaining authors declare no competing interests.